Featured Video
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
15:31 MIN
- CIDP
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
Our Experts
David R. Cornblath, MD
Johns Hopkins University, Baltimore, MD, USA
David R. Cornblath, MD
Johns Hopkins University, Baltimore, MD, USA
- GBS
David R. Cornblath received his MD from Case Western Reserve University and completed his residency and fellowship at the Hospital of the University of Pennsylvania under Prof. A.K. Asbury.
Carol L. Koski, MD
GBS/CIDP Foundation International
Carol L. Koski, MD
GBS/CIDP Foundation International
- CIDP
- GBS
Dr. Koski is a retired Professor of Neurology from the University of Maryland School of Medicine and is currently a Director of the GBS/CIDP Foundation International.
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
- CIDP
Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland.
Michael Lunn, PhD
National Hospital for Neurology and Neurosurgery, Queen Square, London
Michael Lunn, PhD
National Hospital for Neurology and Neurosurgery, Queen Square, London
- CIDP
Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery.
Back to Top